KalVista Pharmaceuticals, Inc. ((KALV)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
KalVista Pharmaceuticals, Inc. is conducting an open-label clinical study titled ‘Open-Label Safety, Pharmacokinetic, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With Hereditary Angioedema Type I or II.’ The study aims to evaluate the safety, pharmacokinetics, and efficacy of KVD900 in young patients with HAE Type I or II, a rare genetic condition causing severe swelling.
The intervention being tested is Sebetralstat (KVD900), an oral drug designed to treat hereditary angioedema. It is administered in three different doses: 150 mg, 300 mg, and 600 mg, to assess its effectiveness and safety in children.
This Phase 3 study is interventional with a non-randomized, parallel assignment model. It is open-label, meaning no masking is involved, and its primary purpose is treatment-focused.
The study began on June 14, 2024, with an estimated primary completion date yet to be announced. The latest update was submitted on September 11, 2025, indicating ongoing recruitment.
This study update could positively impact KalVista’s stock performance by demonstrating progress in developing a pediatric treatment for HAE, potentially boosting investor confidence. The pharmaceutical industry is highly competitive, and advancements in rare disease treatments can significantly influence market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.